Hubungan Stadium Kanker dan Jenis Terapi yang diberikan Dengan Tingkat Kualitas Hidup Penderita Kanker Buli-Buli di RSUP Dr. M. Djamil Padang Tahun 2018–2021

Fikri Fadhil; Alvarino Alvarino; Gardenia Akhyar

doi:10.55606/detector.v2i3.4012

Authors

Fikri Fadhil Universitas Andalas Padang
Alvarino Alvarino RSUP Dr. M. Djamil Padang
Gardenia Akhyar RSUP Dr. M. Djamil Padang

DOI:

https://doi.org/10.55606/detector.v2i3.4012

Keywords:

Bladder cancer, quality of life, age, sex, stage of cancer, type of therapy

Abstract

Quality of life is very important assessment in evaluating a person’s perception of the disease they have. Cancer stage characteristics and the type of therapy given to baldder cancer patients can affect the overall quality of life. This study aims to see the relationship of the stage of cancer and the type of therapy given with the quality of life. The type of this research is an analytical study with a cross sectional design. Sampling was done by consecutive sampling technique. The research took place from August 2021–March 2022 at RSUP Dr. M. Djamil Padang with a total sample of 64 people. The research instrument used was the EORTC QLQ-C30 questionnaire and medical records of patients with bladder cancer. Bladder cancer most often occurs in people with the age of >45 years old and male sex. The most found stage in bladder cancer is stage II and the most frequently implemented therapy is TURBT. Cancer stage and the type of therapy used had a statistically significant relationship with the quality of life of bladder people with the age of >45 years old and male sex. The most found stage in bladder cancer is stage II and the most frequently implemented therapy is TURBT. Cancer stage and the type of therapy used had a statistically significant relationship with the quality of life of bladder cancer patients (p=0.01; p=0.04). There is a significant relationship of the cancer stage and type of therapy given with the quality of life of bladder cancer patients.

Downloads

Download data is not yet available.

References

Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I BF. International Agency for Research on Cancer 2020. Glob Cancer Obs Cancer Today. 2020;419:1-2.

Richters A, Aben KKH, Kiemeney LALM. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895-1904.

Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol. Published online 2020:1-18.

American Cancer Society. Cancer Facts & Figures 2018. In: ; 2018.

Smith B, Milowsky MI. Gender disparities in chemotherapy use and survival in patients with advanced bladder cancer. 2020;122(13):2012-2020.

The Global Cancer Observatory. Cancer Incident in Indonesia. Int Agency Res Cancer. 2020;858:1-2.

Iscan, Hendrizal. Efmansyah DA. Karsinoma buli-buli yang dirawat di bangsal bedah RSUP DR.M.Djamil Padang Tahun 2000-2005. Published online 2006.

RSUP. Kejadian Karsinoma Buli-buli 2018. In: Medical Record RSUP Dr.M.Djamil; 2018.

Yong ZK, Zheng WQ, Lin N, Lin YWY, Tao X. Risk factors for upper tract urothelial recurrence following local excision of bladder cancer. 2018;(June):1-6.

National Institute for Health and Care Excellence. Bladder cancer: diagnosis and management of bladder cancer. BJU Int. 2017;120(6):755-765.

Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37(18):1547-1557.

Zarifmahmoudi L, Ghorbani H, Sadri K, et al. Sentinel Node Biopsy in Urothelial Carcinoma of the Bladder : Systematic Review and Meta-Analysis Urologia. Published online 2019.

Rouanne M, Bajorin DF, Hannan R, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol. (2020):1-11.

Chou YJ, Kuo HJ, Shun SC. Cancer prehabilitation programs and their effects on quality of life. Oncol Nurs Forum. 2018;45(6):726-736.

European Organisation for Research and Treatment of Cancer. EORTC QLQ-C30 Scoring Manual. 2001;30.

Elfarianti B. FAKTOR-FAKTOR YANG BERHUBUNGAN DENGAN TINGKAT KUALITAS HIDUP PENDERITA KANKER PAYUDARA.; 2019.

Bhanvadia SK. Bladder Cancer Survivorship. Published online 2018.

Palareti G, Legnani C, Cosmi B, et al. The impact of bladder cancer on health-related quality of life. Int J Lab Hematol. 2016;38(1):42-49.

W.Rohen, Johannes. Yokochi, Chihiro. Drecoll EL. Color Atlas of Anatomy A Photohgraphic Study of the Human Body. 7th ed.; 2011.

Hansen JT. Netter’s Clinical Anatomy. Vol 47. 3rd ed. (Tannian P, ed.). Elsevier Inc; 2014.

Paulsen F, Waschke J. Sobotta Atlas Anatomi Manusia: Anatomi Umum Dan Muskuloskeletal. 15th ed. Elsevier Inc; 2015.

Gartner LP, Hiatt JL. A Textbook of Histology. Vol 175. 3rd ed. (Ozals I, Mahon J, eds.). Elsevier Inc; 1961.

Mescher AL. Jonqueira’s Basic Histology. Vol 511. 13th ed. Mc Graw-Hill; 2013.

Kellogg J, John B. Handbook of Urology. 1st ed. Wiley Blackwell; 2014.

Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-241.

Rose TL, Deal AM, Nielsen ME, Smith AB, Milowsky MI. Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer. Cancer. 2016;122(13):2012-2020.

Yu Z, Yue W, Jiuzhi L, Youtao J, Guofei Z, Wenbin G. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. Urolithiasis. Published online 2018:573-579.

Guo CC, Czerniak B. Bladder Cancer in the Genomic Era. 2018;11:4.

Carreón T, Hein MJ, Hanley KW, Viet SM, Ruder AM. Bladder cancer incidence among workers exposed to o-toluidine, aniline and nitrobenzene at a rubber chemical manufacturing plant. Occup Environ Med. 2014;71(3):175-182.

Ma S, Zhang T, Jiang L, et al. Impact of bladder volume on treatment planning and clinical outcomes of radiotherapy for patients with cervical cancer. Cancer Manag Res. 2019;11:7171-7181.

Supit W, Mochtar CA, Sugiono M, Umbas R. Survival of patients with transitional cell carcinoma of the urinary bladder in indonesia: A single institution review. Asian Pacific J Cancer Prev. 2011;12(2):549-553.

Kumar, Cotran, Robbins. Buku Ajar Patologi. Vol 2. 7th ed. (Asroruddin M, Hartanto H, Darmaniah N, eds.). EGC; 2007.

Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007;99(7):558-568.

Boldini M, Cerantola Y, Valerio M, Jichlinski P. Urologie. Vol 11.; 2015.

Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol. 2014;65(4):778-792.

Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. Histopathology. 2019;74(1):112-134.

Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur Urol. 2011;59(6):1009-1018.

Umbas R, Hardjowijoto S, Arif C, Safriadi F, Djatisoesanto W, Sihombing AT. Panduan Penanganan Kanker Kandung Kemih Tipe Urotelial.; 2014.

Shakespeare W. Urology A Handbook for Medical Students.; 2014.

Kim LHC, Patel MI. Transurethral resection of bladder tumour (TURBT). Transl Androl Urol. 2021;9(6):3056-3072.

Pietzak EJ, Zabor EC, Bagrodia A, et al. HHS Public Access. 2020;75(2):231-239.

Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615-625.

Kamat AM, Colombel M, Sundi D, et al. BCG-unresponsive non-muscle-invasive bladder cancer: Recommendations from the IBCG. Nat Rev Urol. 2017;14(4):244-255.

Aluwini S, Rooij PHE Van, Kirkels WJ, Boormans JL, Kolkman-deurloo IK, Wijnmaalen A. Bladder Function Preservation With Brachytherapy , External Beam Radiation Therapy , and Limited Surger in Bladder Cancer Patients : Long-Term Results. Radiat Oncol Biol. 2014;88(3):611-617. http://dx.doi.org/10.1016/j.ijrobp.2013.11.227

Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017;123(22):4346-4355.

Prutkin JM, Feinstein AR. Quality-of-life measurements: Origin and pathogenesis. Yale J Biol Med. 2002;75(2):79-93.

Post MWM. Definitions of quality of life: What has happened and how to move on. Top Spinal Cord Inj Rehabil. 2014;20(3):167-180.

Hagen NA, Addington-Hall J, Sharpe M, Richardson A, Cleeland CS. The Birmingham international workshop on supportive, palliative, and end-of-life care research. Cancer. 2006;107(4):874-881.

Sacher RA. Tinjauan Klinis Hasil Pemeriksaan, Laboratorium. (Wulandari D, ed.). EGC; 2012.

Sibeoni J, Picard C, Orri M, et al. Patients’ quality of life during active cancer treatment: A qualitative study. BMC Cancer. 2018;18(1):1-8.

Husson O, Rooij BH, Kieffer J, et al. The EORTC QLQ‐C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the “Real‐World”: Results from the Population‐Based PROFILES Registry. Oncologist. 2020;25(4):1-11.

Mina S, Pardo Munevar CA, Osorio D, García-Perdomo HA. Life quality evaluation in patients with bladder cancer: A systematic review. Actas Urol Esp. 2019;43(4):198-204.

Hevér N V., Péntek M, Balló A, et al. Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. Pathol Oncol Res. 2015;21(3):619-627.

Kemenkes. Sistem Kesehatan Nasional. Published online 2020.

Bladder C, Be C, Early F, et al. Bladder Cancer Early Detection , Diagnosis , and Staging. Am Cancer Soc. Published online 2020:1-24.

Yusuf Y. Panduan Praktek Klinik Kanker Buli RSUP Dr. M. Djamil Padang. Published online 2021.

Effendi ERBB dengan GHKB di RDMDPT 2014-2018. Hubungan Riwayat Batu Buli-Buli Dengan Gambaran Histopatologi Karsinoma Buli-Buli Di RSUP Dr. M. Djamil Padang Tahun 2014-2018.; 2018. http://scholar.unand.ac.id/61716/2/2. BAB 1 (Pendahuluan).pdf

Ifan. Morbiditas Dan Mortalitas Pasca Sistektomi Radikal Pada Kanker Buli Di Rsud Dr Soetomo Surabaya. Kesehatan, Univ Airlangga. Published online 2019.

Shi B, Zhang K, Zhang J, Chen J, Zhang N, Xu Z. Relationship Between Patient Age and Superficial Transitional Cell Carcinoma Characteristics. Urology. 2008;71(6):1186-1190.

Pandu Putra Anugrah, Pandu Ishaq Nandana, Marie Yuni Andari. Insidensi Penyakit Kanker Buli-buli di RSUD Provinsi Nusa Tenggara Barat periode 2017-2018. Unram Med J. 2019;8(2):1-4.

Janisch F, Shariat SF, Schernhammer E, Rink M, Fajkovic H. The interaction of gender and smoking on bladder cancer risks. Curr Opin Urol. 2019;29(3):249-255.

Tripathi A, Gupta S. Androgen receptor in bladder cancer: A promising therapeutic target. Asian J Urol. 2020;7(3):284-290. https://doi.org/10.1016/j.ajur.2020.05.011

Osawa T, Wei JT, Abe T, Honda M, Yamada S, Furumido J. Health ‑ related quality of life in Japanese patients with bladder cancer measured by a newly developed Japanese version of the Bladder Cancer Index. Int J Clin Oncol. 2020;25(12):2090-2098. https://doi.org/10.1007/s10147-020-01770-2

Tyson MD, Barocas DA. Quality of Life After Radical Cystectomy. Urol Clin North Am. 2018;45(2):249-256.

Ripping TM, Kiemeney LA, Hoogstraten LMC Van, Witjes JA, Aben KKH. Insight into bladder cancer care : study protocol of a large nationwide prospective cohort study ( BlaZIB ). Published online 2020:1-7.

Jung A, Nielsen ME, Crandell JL, Mayer DK. Health-Related Quality of Life among Non-Muscle-Invasive Bladder Cancer Survivors: A Population-Based Study Ahrang. 2021;125(1):38-48.

Motterle G, Andrews JR, Morlacco A, Karnes RJ. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol Focus. 2020;6(4):642-649. https://doi.org/10.1016/j.euf.2019.10.016

Matsumoto Y, Samma S, Fukui S, Nakai Y, Kagebayashi Y, Torimoto K. External beam radiation plus concurrent intra-arterial chemotherapy with low dose cisplatin for muscle invasive bladder cancer. Indian J Urol. 2015;31(1):52-56.